

## PART 15 PUBLIC HEARING BEFORE THE COMMISSIONER

### 目录

PART 15PUBLIC HEARING BEFORE THE COMMISSIONER.....	1
Subpart A--General Provisions.....	2
Sec. 15.1 Scope.....	2
Subpart B--Procedures for Public Hearing Before the Commissioner.....	2
Sec. 15.20 Notice of a public hearing before the Commissioner.....	2
Sec. 15.21 Notice of participation; schedule for hearing.....	3
Sec. 15.25 Written submissions.....	4
Sec. 15.30 Conduct of a public hearing before the Commissioner.....	4
Subpart C--Records of a Public Hearing Before the Commissioner.....	6
Sec. 15.40 Administrative record.....	6
Sec. 15.45 Examination of administrative record.....	6

## Subpart A--General Provisions

### Sec. 15.1 Scope.

The procedures in this part apply when:

(a) The Commissioner concludes, as a matter of discretion, that it is in the public interest to permit persons to present information and views at a public hearing on any matter pending before the Food and Drug Administration.

(b) The act or regulation specifically provides for a public hearing before the Commissioner on a matter, e.g., 330.10(a)(8) relating to over-the-counter drugs and sections 520 (b) and (f)(1)(B), and 521 of the act relating to proposals to allow persons to order custom devices, to proposed device good manufacturing practice regulations, and to proposed exemptions from preemption of State and local device requirements under 808.25(e).

(c) A person who has right to an opportunity for a formal evidentiary public hearing under part 12 waives that opportunity and instead requests under 12.32 a public hearing before the Commissioner, and the Commissioner, as a matter of discretion, accepts the request.

## Subpart B--Procedures for Public Hearing Before the Commissioner

### Sec. 15.20 Notice of a public hearing before the Commissioner.

(a) If the Commissioner determines that a public hearing should be held on a matter, the Commissioner will publish a notice of hearing in the Federal Register setting forth the following information:

(1) If the hearing is under 15.1 (a) or (b), the notice will state the

following:

(i) The purpose of the hearing and the subject matter to be considered. If a written document is to be the subject matter of the hearing, it will be published as part of the notice, or reference made to it if it has already been published in the Federal Register, or the notice will state that the document is available from an agency office identified in the notice.

(ii) The time, date, and place of the hearing, or a statement that the information will be contained in a subsequent notice.

(2) If the hearing is in lieu of a formal evidentiary public hearing under 15.1(c), all of the information described in 12.32(e).

(b) The scope of the hearing is determined by the notice of hearing and any regulation under which the hearing is held. If a regulation, e.g., 330.10(a)(10), limits a hearing to review of an existing administrative record, information not already in the record may not be considered at the hearing.

(c) The notice of hearing may require participants to submit the text of their presentations in advance of the hearing if the Commissioner determines that advance submissions are necessary for the panel to formulate useful questions to be posed at the hearing under 15.30(e). The notice may provide for the submission of a comprehensive outline as an alternative to the submission of the text if the Commissioner determines that submission of an outline will be sufficient.

#### **Sec. 15.21 Notice of participation; schedule for hearing.**

(a) The notice of hearing will provide persons an opportunity to file a written notice of participation with the Division of Dockets Management within a specified period of time containing the information specified in the notice, e.g., name of participant, address, phone number, affiliation, if any, topic of presentation and approximate amount of time requested for the presentation. If the public interest requires, e.g., a hearing is to be conducted within a short period of time or is to be primarily attended by individuals without an organizational affiliation, the notice may name a specific FDA employee

and telephone number to whom an oral notice of participation may be given or provide for submitting notices of participation at the time of the hearing. A written or oral notice of participation must be received by the designated person by the close of business of the day specified in the notice.

(b) Promptly after expiration of the time for filing a notice, the Commissioner will determine the amount of time allotted to each person and the approximate time that oral presentation is scheduled to begin. If more than one hearing is held on the same subject, a person will ordinarily be allotted time for a presentation at only one hearing.

(c) Individuals and organizations with common interests are urged to consolidate or coordinate their presentations and to request time for a joint presentation. The Commissioner may require joint presentations by persons with common interests.

(d) The Commissioner will prepare a hearing schedule showing the persons making oral presentations and the time allotted to each person, which will be filed with the Division of Dockets Management and mailed or telephoned before the hearing to each participant.

(e) The hearing schedule will state whether participants must be present by a specified time to be sure to be heard in case the absence of participants advances the schedule.

#### **Sec. 15.25 Written submissions.**

A person may submit information or views on the subject of the hearing in writing to the Division of Dockets Management, under 10.20. The record of the hearing will remain open for 15 days after the hearing is held for any additional written submissions, unless the notice of the hearing specifies otherwise or the presiding officer rules otherwise.

#### **Sec. 15.30 Conduct of a public hearing before the Commissioner.**

(a) The Commissioner or a designee may preside at the hearing, except where a regulation provides that the Commissioner will preside personally. The presiding officer may be accompanied by other FDA employees or other Federal Government employees designated by the Commissioner, who may serve as a panel in conducting the hearing.

(b) The hearing will be transcribed.

(c) Persons may use their allotted time in whatever way they wish, consistent with a reasonable and orderly hearing. A person may be accompanied by any number of additional persons, and may present any written information or views for inclusion in the record of the hearing, subject to the requirements of 15.25. The presiding officer may allot additional time to any person when the officer concludes that it is in the public interest, but may not reduce the time allotted for any person without the consent of the person.

(d) If a person is not present at the time specified for the presentation, the persons following will appear in order, with adjustments for those appearing at their scheduled time. An attempt will be made to hear any person who is late at the conclusion of the hearing. Other interested persons attending the hearing who did not request an opportunity to make an oral presentation will be given an opportunity to make an oral presentation at the conclusion of the hearing, in the discretion of the presiding officer, to the extent that time permits.

(e) The presiding officer and any other persons serving on a panel may question any person during or at the conclusion of the presentation. No other person attending the hearing may question a person making a presentation. The presiding officer may, as a matter of discretion, permit questions to be submitted to the presiding officer or panel for response by them or by persons attending the hearing.

(f) The hearing is informal in nature, and the rules of evidence do not apply. No motions or objections relating to the admissibility of information and views may be made or considered, but other participants may comment upon or rebut all such information and views. No participant may interrupt the presentation of another participant at any hearing for any reason.

(g) The hearing may end early only if all persons scheduled for a later presentation have already appeared or it is past the time specified in the hearing schedule, under 15.21(e), by which participants must be present.

(h) The Commissioner or the presiding officer may, under 10.19, suspend, modify, or waive any provision of this part.

## **Subpart C--Records of a Public Hearing Before the Commissioner**

### **Sec. 15.40 Administrative record.**

(a) The administrative record of a public hearing before the Commissioner consists of the following:

(1) All relevant Federal Register notices, including any documents to which they refer.

(2) All written submissions under 15.25.

(3) The transcript of the oral hearing.

(b) The record of the administrative proceeding will be closed at the time specified in 15.25.

### **Sec. 15.45 Examination of administrative record.**

Section 10.20(j) governs the availability for public examination and copying of each document in the administrative record of the hearing

Hlongmed

龙德

龙德医疗器械服务集团

专业领先的医疗器械法规合作伙伴

临床试验 CRO/CRA/SMO/CRC 合作组织

值得信赖的专业医疗器械行业整体解决方案服务商



电话: 0755-86664989



QQ: 2539440171



邮箱: consultant@hlongmed.com



龙德医疗器械资讯

丰富的医疗器械课程直播平台  
专业的医疗器械服务平台  
齐全的医疗器械交流社区



医课汇

专业的医疗器械医课课程平台  
全面的医疗器械资讯平台  
专业的医疗器械人才培养

专业带去价值, 服务赢来美誉!

邮箱: consultant@hlongmed.com

网址: www.hlongmed.com